CN1456161A - 硫酸阿托品眼用凝胶 - Google Patents
硫酸阿托品眼用凝胶 Download PDFInfo
- Publication number
- CN1456161A CN1456161A CN 02117622 CN02117622A CN1456161A CN 1456161 A CN1456161 A CN 1456161A CN 02117622 CN02117622 CN 02117622 CN 02117622 A CN02117622 A CN 02117622A CN 1456161 A CN1456161 A CN 1456161A
- Authority
- CN
- China
- Prior art keywords
- atropine sulfate
- gel
- eye
- hydroxypropyl methylcellulose
- atropine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 title claims abstract description 42
- 229960002028 atropine sulfate Drugs 0.000 title claims abstract description 42
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 13
- 229910021538 borax Inorganic materials 0.000 claims abstract description 12
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 12
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004327 boric acid Substances 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 206010022941 Iridocyclitis Diseases 0.000 claims abstract description 4
- 201000004612 anterior uveitis Diseases 0.000 claims abstract description 4
- -1 phenylmethylhydroxy Chemical group 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 11
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- 208000006550 Mydriasis Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002179 ephedrine Drugs 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000013521 mastic Substances 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 229960000396 atropine Drugs 0.000 claims description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 229930003347 Atropine Natural products 0.000 claims description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 2
- 229940100655 ophthalmic gel Drugs 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 235000010338 boric acid Nutrition 0.000 abstract 1
- 210000001747 pupil Anatomy 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 description 4
- 239000003885 eye ointment Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000026 apposition eye Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02117622 CN1206988C (zh) | 2002-05-10 | 2002-05-10 | 硫酸阿托品眼用凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02117622 CN1206988C (zh) | 2002-05-10 | 2002-05-10 | 硫酸阿托品眼用凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1456161A true CN1456161A (zh) | 2003-11-19 |
CN1206988C CN1206988C (zh) | 2005-06-22 |
Family
ID=29410327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02117622 Expired - Lifetime CN1206988C (zh) | 2002-05-10 | 2002-05-10 | 硫酸阿托品眼用凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1206988C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322683B (zh) * | 2008-07-30 | 2013-01-16 | 浙江三叶药业有限公司 | 一种含有溴芬酸钠水合物的眼用凝胶剂及其制备方法 |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
CN107456440A (zh) * | 2017-08-07 | 2017-12-12 | 杭州赫尔斯科技有限公司 | 一种低浓度阿托品类药物滴眼液及其制备方法 |
CN107982212A (zh) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | 一种阿托品类药物缓释滴眼液及其制备方法 |
US10813923B1 (en) | 2015-04-23 | 2020-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11052095B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
-
2002
- 2002-05-10 CN CN 02117622 patent/CN1206988C/zh not_active Expired - Lifetime
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322683B (zh) * | 2008-07-30 | 2013-01-16 | 浙江三叶药业有限公司 | 一种含有溴芬酸钠水合物的眼用凝胶剂及其制备方法 |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
US9770447B2 (en) | 2014-06-24 | 2017-09-26 | Sydnexis, Inc. | Ophthalmic composition |
US11896588B2 (en) | 2014-06-24 | 2024-02-13 | Sydnexis, Inc. | Ophthalmic composition |
US11890277B2 (en) | 2014-06-24 | 2024-02-06 | Sydnexis, Inc. | Ophthalmic composition |
US10076515B2 (en) | 2014-06-24 | 2018-09-18 | Sydnexis, Inc. | Ophthalmic Composition |
US10201534B2 (en) | 2014-06-24 | 2019-02-12 | Sydnexis, Inc. | Ophthalmic composition |
US11883390B2 (en) | 2014-06-24 | 2024-01-30 | Sydnexis, Inc. | Ophthalmic composition |
US10842787B2 (en) | 2014-06-24 | 2020-11-24 | Sydnexis, Inc. | Ophthalmic composition |
US10864208B2 (en) | 2014-06-24 | 2020-12-15 | Sydnexis, Inc. | Ophthalmic composition |
US11596625B2 (en) | 2014-06-24 | 2023-03-07 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
US10953002B2 (en) | 2015-04-23 | 2021-03-23 | Sydnexis, Inc. | Ophthalmic composition |
US10940145B2 (en) | 2015-04-23 | 2021-03-09 | Sydnexis, Inc. | Ophthalmic composition |
US10888557B2 (en) | 2015-04-23 | 2021-01-12 | Sydnexis, Inc. | Ophthalmic composition |
US10813923B1 (en) | 2015-04-23 | 2020-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US11052095B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
CN107456440A (zh) * | 2017-08-07 | 2017-12-12 | 杭州赫尔斯科技有限公司 | 一种低浓度阿托品类药物滴眼液及其制备方法 |
CN107982212A (zh) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | 一种阿托品类药物缓释滴眼液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1206988C (zh) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107456440A (zh) | 一种低浓度阿托品类药物滴眼液及其制备方法 | |
CN106074568A (zh) | 一种用于预防和治疗白内障的眼用制剂及其制备方法 | |
CN101716214A (zh) | 含有蒲公英提取物的药物组合物及其新用途和制备方法 | |
Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
CN1456350A (zh) | 环孢素眼用凝胶 | |
CN1456161A (zh) | 硫酸阿托品眼用凝胶 | |
CN102512467A (zh) | 一种三七总皂苷的眼用制剂及其制备方法 | |
CN100418530C (zh) | 一种酮康唑滴眼液及其制造方法 | |
CN101366726A (zh) | 一种治疗皮肤疾病的药物组合物 | |
CN102008488B (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
Cleghorn et al. | The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate) | |
CN1132584C (zh) | 一种治疗近视的滴眼剂 | |
CN101559046A (zh) | 小分子糖醇组合物对鼻部疾病的治疗作用 | |
CN101278895A (zh) | 一种眼用即型凝胶制剂及其制备方法 | |
CN1194685C (zh) | 硝酸毛果芸香碱眼用凝胶 | |
CN100563628C (zh) | 一种苄达赖氨酸眼用凝胶制剂及其制备方法 | |
CN113041217A (zh) | 一种含环糊精或环糊精衍生物的石杉碱甲水溶性滴眼液及其制备方法和应用 | |
CN1180776C (zh) | 凝胶型氧氟沙星眼膏 | |
CN1311842C (zh) | 一种治疗慢性结膜炎的药物及其制备方法 | |
CN112535690A (zh) | 供氧与杀菌二合一的三氧眼部清洗护理洗剂 | |
CN103417566A (zh) | 含氢滴眼液及其制备方法和用途 | |
CN115212200B (zh) | 用于治疗糖尿病并发症的含葛根素的复方制剂及其制备方法 | |
CN1247227C (zh) | 一种治疗螨虫感染性皮肤疾病的外用脂质体制剂 | |
CN1456157A (zh) | 左旋氧氟沙星眼用凝胶 | |
Hoffman et al. | Anamp'by any other name: the hazards of intravenous magnesium dosing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenyang Sinqi Pharmaceutical Co., Ltd. Assignor: Liu Jidong Contract fulfillment period: 2005.7.7 to 2010.7.7 Contract record no.: 2008210000059 Denomination of invention: Eye gel for atropine sulfate Granted publication date: 20050622 License type: Exclusive license Record date: 20081106 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2005.7.7 TO 2010.7.7; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081106 |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20111013 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111013 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027, Liaoning, Shenyang economic and Technological Development Zone, No. three, 12, No. 4, Shenyang Xing Qi Pharmaceutical Co., Ltd. Patentee before: Liu Jidong |
|
C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: Shenyang Sinqi Pharmaceutical Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20050622 |
|
CX01 | Expiry of patent term |